frontiers in Cell and Developmental Biology

TYPE Correction
PUBLISHED 01 May 2026
DOI 10.3389/fcell.2026.1852559

Check for updates

OPEN ACCESS

EDITED AND REVIEWED BY
Francesca Pagliari,
German Cancer Research Center (DKFZ), Germany

*CORRESPONDENCE
Glenn E. Simmons Jr.,
glenn.simmons@cornell.edu

†These authors share first authorship

RECEIVED 10 April 2026
REVISED 10 April 2026
ACCEPTED 17 April 2026
PUBLISHED 01 May 2026

CITATION
Cole-Skinner B, Andre NM, Blankenheim Z, Root KM, Jafri K, Simmons GE Jr. (2026) Correction: Oleate alters the immune response in non-small cell lung adenocarcinoma through regulation of HMGB1 release. *Front. Cell Dev. Biol.* 14:1852559. doi: 10.3389/fcell.2026.1852559

COPYRIGHT
© 2026 Cole-Skinner, Andre, Blankenheim, Root, Jafri and Simmons. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Correction: Oleate alters the immune response in non-small cell lung adenocarcinoma through regulation of HMGB1 release

Breanna Cole-Skinner[1†], Nicole M. Andre[2†], Zachary Blankenheim[3], Kate M. Root[3], Kisa Jafri[2] and Glenn E. Simmons Jr.[2*]

[1]Department of Molecular Microbiology and Immunology, University of Missouri, Columbia, United States, [2]Department of Biomedical Sciences, College of Veterinary Medicine, Cornell University, Ithaca, United States, [3]Department of Biomedical Sciences, School of Medicine, University of Minnesota, Duluth, United States

KEYWORDS
HMGB1 (high mobility group box 1), lung cancer, tumor microenvironment, fatty acid, immunotherapy

A Correction on
Oleate alters the immune response in non-small cell lung adenocarcinoma through regulation of HMGB1 release

by Cole-Skinner B, Andre NM, Blankenheim Z, Root KM, Jafri K and Simmons GE Jr. (2024). Front. Cell Dev. Biol. 12:1348707. doi: 10.3389/fcell.2024.1348707

There was a mistake in Figure 5A as published. Experiments that were carried out on H1299 and H23 lung cancer cell lines were not carried out as described for A549 and HCC827. The corrected Figure 5A appears below, with the removal of those two cell lines.

There was a mistake in the caption of Figure 5A as published. The caption for Figure 5A originally stated "MUFA increases retention of HMGB1 in lung cancer cells in a SIRT-dependent manner. (A) Immunoblot protein analysis of multiple lung cancer cells lines treated with delipidation media (delipidated serum and 1 μM SCD1 inhibitor) and 4-h replenishment with oleate-BSA". The corrected caption of Figure 5A appears below.

The original article has been updated.

Generative AI statement

Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.




FIGURE 5
MUFA increases retention of HMGB1 in lung cancer cells in a SIRT-dependent manner. **(A)** Immunoblot protein analysis of KRAS G12S mutant (A549) and EGFR deletion mutant (HCC827) lung cancer cells lines treated with delipidation media (delipidated serum and 1 μM SCD1 inhibitor) and 4-h replenishment with oleate-BSA. **(B)** HMGB1-specific ELISA on extracellular media from A549 and HCC827 lung cancer cells following 16-h delipidation and 4-h oleate-BSA replenishment. **(C)** Fluorescence microscopy of HMGB1-GFP transfected A549 cells following 16-h delipidation and 4-h oleate-BSA replenishment and neutral lipid staining with Nile Red, along with quantitation of localization of HMGB1-GFP sig nals. **(D)** Immunoblot protein analysis of HMGB1-GFP transfected A549 cells from **(C)**. **(E)** Immunoblot protein analysis of A549 lung cancer cells treated SIRT1 inhibitor cambinol for 24-h. **(F)** HMGB1-specific ELISA on extracellular media from cells treated in **(E)**. **(G)** Immunoblot protein analysis of A549 cells treated with combination of cambinol and SCD1 inhibitor in the presence and oleateBSA. **(H)** HMGB1-specific ELISA on extracellular media obtained from cells treated with SIRT1 and SCD1 inhibitors in **(G)**. **(I)** Immunoblot protein analysis of delipidated A549 cells replenished with oleic acid-BSA, 72 h after transfection with SIRT1-specific siRNA. Error bars represent the standard error of the mean (S.E.M.), an *, indicates a p-value < 0.05.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.